|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 913.05 INR | -0.17% |
|
-0.94% | -0.14% |
Business description: Zydus Lifesciences Limited
Number of employees: 27,917
Sales by Activity: Zydus Lifesciences Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 133B | 133B | 150B | 172B | 205B |
Consumer Products | 18.41B | 19.79B | 22.45B | 23.12B | 26.98B |
Geographical breakdown of sales: Zydus Lifesciences Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
United States | 65.44B | 59.49B | 74.87B | 87.75B | 111B |
India | 64.62B | 72.53B | 76.4B | 80.15B | 92.53B |
Others | 20.96B | 20.63B | 21.11B | 27.57B | 28.47B |
Executive Committee: Zydus Lifesciences Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 2009-11-26 | |
| Director of Finance/CFO | 65 | - | |
| Director of Finance/CFO | 56 | 2025-08-31 | |
| Compliance Officer | - | 2019-02-06 | |
Arvind Bothra
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Zydus Lifesciences Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 46 | 2007-03-31 | |
| Director/Board Member | 71 | 1997-07-31 | |
| Chairman | 73 | 2011-10-04 | |
| Director/Board Member | 70 | 2017-07-11 | |
| Director/Board Member | 57 | 2003-08-15 | |
| Director/Board Member | 74 | 2018-12-05 | |
Akhil Monappa
BRD | Director/Board Member | 46 | 2022-11-28 |
| Director/Board Member | 39 | 2022-11-28 | |
| Director/Board Member | - | 2024-05-16 |
Holdings: Zydus Lifesciences Limited
| Name | Equities | % | Valuation |
|---|---|---|---|
ZYDUS WELLNESS LIMITED 57.59% | 183,237,545 | 57.59% | 888 M $ |
AGENUS INC. 6.27% | 2,133,333 | 6.27% | 6 M $ |
Company details: Zydus Lifesciences Limited
Zydus Lifesciences Ltd.
Zydus Corporate Park
382481, Ahmedabad
+91 79 4804 0000
http://www.zyduscadila.com
Group companies: Zydus Lifesciences Limited
| Name | Category and Sector |
|---|---|
Zydus Wellness Products Ltd.
 Zydus Wellness Products Ltd. Pharmaceuticals: OtherHealth Technology Manufactures health and wellness products |
Pharmaceuticals: Other
|
Food: Major Diversified
| |
Food: Major Diversified
| |
Zydus Pharmaceuticals Ltd.
 Zydus Pharmaceuticals Ltd. Medical DistributorsDistribution Services Distributes pharmaceuticals and cosmetics products |
Medical Distributors
|
Zydus Pharmaceuticals Ltd.
Zydus Pharmaceuticals Ltd. Medical DistributorsDistribution Services Distributes pharmaceuticals and cosmetics products |
Medical Distributors
|
Generic Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | -0.94% | +1.36% | +91.76% | 10B | |
| +0.83% | +3.59% | +11.81% | +86.42% | 46.98B | |
| -1.08% | -6.07% | +35.47% | +149.13% | 33.69B | |
| -4.02% | -7.39% | +292.80% | +1,238.00% | 11.96B | |
| -0.39% | -2.00% | -9.41% | +49.98% | 11.61B | |
| +5.59% | +3.46% | +71.48% | +46.60% | 8.21B | |
| -0.86% | -4.17% | +37.31% | +120.10% | 8.13B | |
| +1.12% | -5.74% | +53.86% | -11.04% | 7.52B | |
| +0.73% | -0.58% | +51.27% | +404.43% | 6.52B | |
| -1.54% | -3.77% | +10.48% | +52.79% | 6.2B | |
| Average | +0.02% | -1.96% | +55.64% | +222.82% | 15.08B | |
| Weighted average by Cap. | -0.06% | -1.33% | +45.43% | +196.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Company Zydus Lifesciences Limited
Select your edition
All financial news and data tailored to specific country editions
